NCT04295252Recruiting
Altshock-2 REGISTRY
Cardiogenic Shock: a Prospective National Registry to Get Insights in Patients' Profile, Management and Outcome
Source: ClinicalTrials.gov · Last updated 14 May 2026
Brief summary (registry, in English)
The study will provide data on profile, management, outcome, and evolution over time of cardiogenic shock patients admitted to the Intensive Coronary Care Units
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 2 Mar 2020
- Start date
- Jul 2020
- Primary completion date
- Dec 2030
- Lead sponsor
- Niguarda Hospital
- NCT number
- NCT04295252
What you commit to
- Study type: Observational
- Planned participants: 3000
- From Jul 2020 to the primary completion date, Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- All consecutive CS patients hospitalized in the above reported centres between January 2020 and December 2030.
- Cardiogenic shock is defined as:
- Systolic blood pressure (SBP) \<90 mmHg or mean arterial pressure (MAP) \<60 mmHg, after an appropriate fluid challenge if there is no sign of overt fluid overload, OR need of vasoactive agents to maintain SBP \> 90 mmHg or MAP \> 60 mmHg, OR need of MCS;
- At least one of the following criteria/signs of overt hypoperfusion: mixed venous oxygen saturation \<60%; arterial lactates \> 2 mmol/L; oliguria \< 0.5 ml/Kg/h for at least 6 hours.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ASST GOM Niguarda Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.